Lv2
106 积分 2023-07-04 加入
Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALD
17天前
已完结
Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial
17天前
已完结
Overall Survival and Exploratory Biomarker Analyses of Abemaciclib plus Trastuzumab with or without Fulvestrant versus Trastuzumab plus Chemotherapy in HR+, HER2+ Metastatic Breast Cancer Patients
21天前
已完结
Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer
23天前
已完结
Should regional nodal irradiation be omitted in patients with node-positive breast cancer converting to node-negative after neoadjuvant chemotherapy?
1个月前
已完结
Should regional nodal irradiation be omitted in patients with node-positive breast cancer converting to node-negative after neoadjuvant chemotherapy?
1个月前
已关闭
Hypo- Versus Standard Fractionated Locoregional Radiotherapy of Patients With High-Risk Breast Cancer in the Randomized Phase III Trial: The Danish Breast Cancer Group Skagen Trial 1
1个月前
已完结
Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2 -Negative Breast Cancer
1个月前
已完结
Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER)
1个月前
已完结
The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer
1个月前
已完结
皖公网安备34019202002308
